Dexamethason Sodium Phosphate Injection 4mg/1ml

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: Injection
Still deciding? Get samples of $ !
Request Sample

360° Virtual Tour

Diamond Member Since 2025

Suppliers with verified business licenses

Audited Supplier Audited Supplier

Audited by an independent third-party inspection agency

High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Years of Export Experience
The export experience of the supplier is more than 10 years
Exhibition Experience
The supplier had participated in offline trade shows, you can check the Audit Report for more information
Experienced Team
The supplier has 18 foreign trading staff(s) and 6 staff(s) with over 6 years of overseas trading experience
to see all verified strength labels (26)
  • Dexamethason Sodium Phosphate Injection 4mg/1ml
  • Dexamethason Sodium Phosphate Injection 4mg/1ml
  • Dexamethason Sodium Phosphate Injection 4mg/1ml
  • Dexamethason Sodium Phosphate Injection 4mg/1ml
  • Dexamethason Sodium Phosphate Injection 4mg/1ml
  • Dexamethason Sodium Phosphate Injection 4mg/1ml
Find Similar Products

Basic Info.

Model NO.
AMC14010-01
Suitable for
Elderly, Children, Adult
State
Liquid
Shape
Injection
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
OEM/ODM
Support
Standard Available
Bp, Cp
Function
Hormones
Delivery Time
30-60 Days
Transport Package
Carton
Specification
4mg/1ml
Trademark
Shinepharm
Origin
China
HS Code
3004320099
Production Capacity
2000000 Box Per Month

Product Description

Dexamethason Sodium Phosphate Injection 4mg/1ml

DEXAMETHASONE SODIUM PHOSPHATE INJECTION  4mg 1ml

Dexamethasone Sodium Phosphate Injection Composition:

Each ampoule contains 4mg Dexam. phosphate,

Dexamethasone Sodium Phosphate Injection Pharmacological Action:

Dexamethasone Sodium Phosphate Injection acts by controlling the rate of protein synthesis: It forms a steroid-receptor complex with receptor proteins, moves into the nucleus where it binds the chromatin and thus directs the genetic apparatus to transcribe RNA. It has a biological half-life in plasma of about 190 minutes and has relatively very weak sodium retaining properties.

Dexamethasone Sodium Phosphate Injection Indications:

Conditions: where the anti inflammatory and immunosuppressive effects of a corticosteroid are desirable, including intensive treatment during shorter periods.

Dexamethasone Sodium Phosphate Injection Contra-Indications:

Sensitive to corticosteroids, Tuberculosis, Ocular herpes simplex, Primary glaucoma. Acute psychosis and psychoneurosis, Systemic infection, Peptic ulcer, Osteoporosis.

Dexamethasone Sodium Phosphate Injection Warning:

Dexamethasone Sodium Phosphate Injection should not be administered intrathecally or subconjunctivally. Toxic effects may result from withdrawal or from continued use of large doses. Dexamethasone Sodium Phosphate Injection should be used with extreme caution in the presence of congestive heart failure, hypertension, in patients with diabetes mellitus, infectious diseases, chronic renal failure, uraemia and in elderly patients.

Dexamethasone Sodium Phosphate Injection Dosage and indications for use.:

Usual adult dosage ranges from 0,5 to 20 mg daily depending on the severity of the disorder. Dexamethasone Sodium Phosphate Injection may be administered intravenously or intramuscularly. The parenteral administration must be reserved for administration in emergencies or ad intensive therapy. Intra-articular, intralesional intra-muscular or soft-tissue injection: 0,8 to 4mg (depending on the size of the joint).

Dexamethasone Sodium Phosphate Injection Side-effects:

Dexamethasone Sodium Phosphate Injection has little or no effect on sodium and water retention. Oedema, hypertension and an increased excretion of potassium with the possibility of hypokalaemic alkalosis may occur. Cardiac failure may be induced. Excessive metabolic effects may lead to mobilisation of calcium and phosphorous, with osteoporosis and spontaneous fractures, nitrogen depletion and hypergtycaemia with accentuation or precipitation of the diabetic state. The insulin requirements of diabetic patients are increased. Increased appetite is reported. The effect on tissue repair is manifest in delayed wound healing and increased susceptibility to all kinds of infection: including sepsis, fungal and viral infections have been reported, especially if patients are given antibiotics conjointly. Infections may also be masked. Acute adrenal insufficiency may occur during prolonged treatment or on cessation of treatment and may be precipitated by an infection or trauma. Growth retardation in children has been reported. Large doses may produce symptoms typical of hyperactivity of the adrenal cortex with moon-face sometimes with hirsutism, buffalo hump, flushing, increased bruising, striae, and acne, sometimes leading to fully developed Cushing's syndrome, Sudden cessation of administration is dangerous. Withdrawal should therefore always be gradual, the rate depending upon the individual patient's response, the dose, the disease being treated and the duration of therapy. Adrenal function should be monitored throughout withdrawal and symptoms attributable to over-rapid withdrawal should be countered by resuming a higher dose and continuing the reduction at a slower rate.

Dexamethasone Sodium Phosphate Injection Storage:

Store below 25ºC. Protect from light. Keep out of reach of children.


Dexamethason Sodium Phosphate Injection 4mg/1mlDexamethason Sodium Phosphate Injection 4mg/1mlDexamethason Sodium Phosphate Injection 4mg/1mlDexamethason Sodium Phosphate Injection 4mg/1ml

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier